全文获取类型
收费全文 | 2318篇 |
免费 | 139篇 |
国内免费 | 14篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 52篇 |
妇产科学 | 67篇 |
基础医学 | 287篇 |
口腔科学 | 24篇 |
临床医学 | 174篇 |
内科学 | 796篇 |
皮肤病学 | 16篇 |
神经病学 | 184篇 |
特种医学 | 85篇 |
外科学 | 298篇 |
综合类 | 4篇 |
一般理论 | 3篇 |
预防医学 | 170篇 |
眼科学 | 38篇 |
药学 | 85篇 |
中国医学 | 15篇 |
肿瘤学 | 156篇 |
出版年
2024年 | 3篇 |
2023年 | 20篇 |
2022年 | 38篇 |
2021年 | 70篇 |
2020年 | 30篇 |
2019年 | 63篇 |
2018年 | 63篇 |
2017年 | 56篇 |
2016年 | 43篇 |
2015年 | 55篇 |
2014年 | 99篇 |
2013年 | 108篇 |
2012年 | 174篇 |
2011年 | 224篇 |
2010年 | 116篇 |
2009年 | 93篇 |
2008年 | 156篇 |
2007年 | 138篇 |
2006年 | 136篇 |
2005年 | 111篇 |
2004年 | 133篇 |
2003年 | 114篇 |
2002年 | 113篇 |
2001年 | 39篇 |
2000年 | 32篇 |
1999年 | 40篇 |
1998年 | 22篇 |
1997年 | 12篇 |
1996年 | 17篇 |
1995年 | 6篇 |
1994年 | 11篇 |
1993年 | 11篇 |
1992年 | 17篇 |
1991年 | 16篇 |
1990年 | 14篇 |
1989年 | 12篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1986年 | 6篇 |
1985年 | 5篇 |
1984年 | 6篇 |
1979年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1974年 | 3篇 |
1972年 | 2篇 |
1970年 | 4篇 |
1969年 | 2篇 |
1968年 | 3篇 |
1967年 | 2篇 |
排序方式: 共有2471条查询结果,搜索用时 15 毫秒
61.
62.
63.
Luis Castells Victor Vargas Antonio Gonzalez Juan Esteban Rafael Esteban Jaume Guardia 《Liver international》1995,15(3):159-163
Abstract: A high prevalence of HCV infection has been reported in patients with hepatocellular carcinoma. The progression from acute transfusion-associated hepatitis to hepatic cirrhosis and hepatocellular carcinoma has been suggested in several studies to be very long. We have investigated the prevalence of anti-HCV and the interval between HCV infection and hepatocellular carcinoma among 191 consecutive patients with cirrhosis and liver-cell carcinoma. Serum samples from 191 patients with cirrhosis and hepatocellular carcinoma, consecutively diagnosed in our hospital between 1988 and 1993, were tested for serological markers of HBV and HCV infection. One hundred and forty-eight patients (77.5%; 95% confidence interval (c.i): 76% to 80%) were anti-HCV positive by 2nd generation enzyme immunoassay (confirmed by 2nd generation recombinant immunoblot assay) and 152 patients (79.5%; 95% c.i: 76% to 80%) were anti-HCV positive by 3rd generation enzyme immunoassay, while only 14 (7.4%; 95% c.i: 5% to 10%) were HBsAg positive. Of the 29 anti-HCV positive patients with previous transfusion, the interval between the date of blood transfusion and the diagnosis of hepatic cirrhosis was 24±12.5 years and that of hepatocellular carcinoma was 26.8±12.4 years. These results confirm the high prevalence of HCV infection in patients with hepatocellular carcinoma and the slow sequential progression from HCV infection through cirrhosis and hepatocellular carcinoma. 相似文献
64.
José Miguel Baena-Díez Isaac Subirana Rafael Ramos Agustín Gómez de la Cámara Roberto Elosua Joan Vila Alejandro Marín-Ibáñez María Jesús Guembe Fernando Rigo María José Tormo-Díaz Conchi Moreno-Iribas Joan Josep Cabré Antonio Segura José Lapetra Miquel Quesada María José Medrano Paulino González-Diego Guillem Frontera Jaume Marrugat 《Revista espa?ola de cardiología》2018,71(4):274-282
Introduction and objectives
To assess the validity of the original low-risk SCORE function without and with high-density lipoprotein cholesterol and SCORE calibrated to the Spanish population.Methods
Pooled analysis with individual data from 12 Spanish population-based cohort studies. We included 30 919 individuals aged 40 to 64 years with no history of cardiovascular disease at baseline, who were followed up for 10 years for the causes of death included in the SCORE project. The validity of the risk functions was analyzed with the area under the ROC curve (discrimination) and the Hosmer-Lemeshow test (calibration), respectively.Results
Follow-up comprised 286 105 persons/y. Ten-year cardiovascular mortality was 0.6%. The ratio between estimated/observed cases ranged from 9.1, 6.5, and 9.1 in men and 3.3, 1.3, and 1.9 in women with original low-risk SCORE risk function without and with high-density lipoprotein cholesterol and calibrated SCORE, respectively; differences were statistically significant with the Hosmer-Lemeshow test between predicted and observed mortality with SCORE (P < .001 in both sexes and with all functions). The area under the ROC curve with the original SCORE was 0.68 in men and 0.69 in women.Conclusions
All versions of the SCORE functions available in Spain significantly overestimate the cardiovascular mortality observed in the Spanish population. Despite the acceptable discrimination capacity, prediction of the number of fatal cardiovascular events (calibration) was significantly inaccurate.Full English text available from:www.revespcardiol.org/en 相似文献65.
66.
Knobel H Escobar I Polo R Ortega L Martín-Conde MT Casado JL Codina C Fernández J Galindo MJ Ibarra O Llinas M Miralles C Riera M Fumaz CR Segador A Segura F Chamorro L 《Enfermedades infecciosas y microbiología clínica》2005,23(4):221-231
Since the early days of antiretroviral therapy, adherence has emerged as the milestone of success; in fact, it is the most potent predictor of effectiveness. The main factors related to adherence include the complexity of the therapeutic regimen, adverse effects, psychological problems, alcoholism and active addiction to drugs, lack of social and family support and the patient's beliefs and attitudes about the treatment. Adherence monitoring should be part of the HIV patient's regular care, and should be done with feasible, easily applied methods adapted to the different clinical settings. The minimally acceptable measures should include use of a validated questionnaire, together with data from the Pharmacy Department's drug dispensation registry. All patients that begin HAART or undergo a change of treatment should participate in a treatment education program imparted by health professionals with knowledge and experience in the management of patients with HIV infection. The health team (doctors, pharmacists and nursing professionals) should offer maximum availability to solve the doubts and problems that may occur during treatment. When sub-optimal adherence is detected, intervention strategies based on psychological therapy, educational efforts and personal advice should be attempted, in order to adapt the treatment scheme to the patient's habits and provide solutions to the problem of non-compliance. In certain situations, co-morbid conditions will also require attention. Treatment adherence, being a multidimensional problem, needs a multidisciplinary team approach. The choice of therapy, only one aspect of the multidimensional problem of adherence, must be a careful and individualized decision; however, simpler regimens with regard to the number of pills and daily dose are desirable. 相似文献
67.
Olivera Grbovic-Huezo Kenneth L. Pitter Nicolas Lecomte Joseph Saglimbeni Gokce Askan Matilda Holm Jerry P. Melchor Rohit Chandwani Suhasini Joshi Caj Haglund Christine A. Iacobuzio-Donahue Gabriela Chiosis Tuomas Tammela Steven D. Leach 《Proceedings of the National Academy of Sciences of the United States of America》2020,117(48):30670
68.
Jaume Miranda-Rius Lluís Brunet-Llobet Eduard Lahor-Soler Magí Farré 《International journal of medical sciences》2015,12(10):811-824
Background: Salivary secretory disorders can be the result of a wide range of factors. Their prevalence and negative effects on the patient''s quality of life oblige the clinician to confront the issue.Aim: To review the salivary secretory disorders, inducing drugs and their clinical management.Methods: In this article, a literature search of these dysfunctions was conducted with the assistance of a research librarian in the MEDLINE/PubMed Database.Results: Xerostomia, or dry mouth syndrome, can be caused by medication, systemic diseases such as Sjögren''s Syndrome, glandular pathologies, and radiotherapy of the head and neck. Treatment of dry mouth is aimed at both minimizing its symptoms and preventing oral complications with the employment of sialogogues and topical acting substances. Sialorrhea and drooling, are mainly due to medication or neurological systemic disease. There are various therapeutic, pharmacologic, and surgical alternatives for its management. The pharmacology of most of the substances employed for the treatment of salivary disorders is well-known. Nevertheless, in some cases a significant improvement in salivary function has not been observed after their administration.Conclusion: At present, there are numerous frequently prescribed drugs whose unwanted effects include some kind of salivary disorder. In addition, the differing pathologic mechanisms, and the great variety of existing treatments hinder the clinical management of these patients.The authors have designed an algorithm to facilitate the decision making process when physicians, oral surgeons, or dentists face these salivary dysfunctions. 相似文献
69.